The Blackstone Group, a major US private equity firm, has announced the acquisition of Takeda Consumer Healthcare Company (TCHC), a subsidiary of Takeda Pharmaceutical. Investment funds and other industries have been putting out feelers toward the pharmaceutical sector in recent…
HOME > BUSINESS
BUSINESS
- Sawai, Susmed Pair Up in Digital Healthcare Field
September 28, 2020
- Shionogi Delays Saliva-Based COVID-19 Test Launch to December
September 25, 2020
- Astellas, Univ. of Pittsburgh Ink Research Pact for Dry AMD
September 25, 2020
- Taiho Hooks Up with MD Anderson on Refractory Cancers
September 25, 2020
- Sawai Can Set Itself Apart from Competitors in Post-80% Generic Era through Development Strategy: President
September 25, 2020
- Daiichi Sankyo Sets Up Subsidiary in Vietnam
September 25, 2020
- Ohara Files Neuroblastoma Drug Dinutuximab in Japan
September 25, 2020
- LTL Pharma Looks to Acquire More Off-Patent Brands with Dellegra as a Catalyst
September 24, 2020
- Opdivo Improves PFS in 1st Line Gastric Cancer: Asian PII/III Trial
September 24, 2020
- Padcev Extends Survival in Bladder Cancer, Trial Stopped Early: Astellas/Seattle Genetics
September 24, 2020
- Sun Pharma Launches Ilumya; Its First Innovative Med in Japan
September 24, 2020
- Sumitomo Dainippon Sets Up Subsidiary in Taiwan
September 24, 2020
- Avigan Hits Primary Goal for Novel Coronavirus, Filing Eyed in October: Fujifilm
September 24, 2020
- Lenvima/Keytruda Combo Shows around 30% ORR in Triple Negative Breast Cancer, Ovarian Cancer: PII
September 24, 2020
- Keytruda’s 1st Line Gastric Cancer Submission Pulled in Japan
September 23, 2020
- 42 Nippon Chemiphar Reps to Hit Exit under Voluntary Redundancy
September 23, 2020
- Sanofi’s Dupixent Adds Pen Formulation in Japan
September 23, 2020
- Lucentis Biosimilar Filed in Japan; Senju/Gene Techno Eye 2021 Approval
September 23, 2020
- Kyowa Kirin Sees Steady Switch to Nesp Biosame, but Biosimilars Closing in at Full Steam
September 18, 2020
- Santen Gobbles Up US Ophthalmic Player for US$225 Million
September 18, 2020
ページ
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Despite the worldwide focus on inclusivity and diversity, it will take immediate action to counteract Japan’s growing gender gap. Study after study has proven that companies with more women in senior roles perform better financially, gaining a competitive edge from…